BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

WuXi Biologics Launches a New GMP Commercial Drug Product Facility

Enhances drug product services for projects at various stages, with an emphasis on late and commercial stage production Increases up to 60 million vials...

November 01, 2021 | News

WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed a remote G...

October 28, 2021 | News

Samsung Biologics Reports Third Quarter 2021 Financial Results

Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20. Q3'21 operating profit of KRW 167.4 billion increased 196% compa...

October 27, 2021 | News

Chinese BioPharma I-Mab Expands U.S. Footprint with New R&D Site

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel bi...

October 25, 2021 | News

AstraZeneca launches Clinical Data and Insights division in India

The Clinical Data & Insights team in Bengaluru, India, is a critical advancement to support a growing global portfolio, and build on internal data expe...

October 20, 2021 | News

BioAgilytix Closes Acquisition of Australia-based 360biolabs®

360biolabs®, the most comprehensive contract research organization in Australia and New Zealand, has now officially joined forces with BioAgilytix Labs...

October 14, 2021 | News

Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy

Expansion in Carlsbad, California, USA, doubles production capacity to support commercialization and industrialization of viral vectors Investment ...

October 13, 2021 | News

CPhI Report predicts record EBITDAs for CDMOs in 2022

Part one of the 2021 CPhI Annual Report predicts an increasingly bullish outlook for CDMOs in the next 2-3 years, with macro factors significantl...

September 28, 2021 | News

Samsung Biologics introduced its CDO process platform, S-Cellerate(TM), at BPI 2021

Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-CellerateTM, at t...

September 23, 2021 | News

WuXi Biologics Completes SARS-CoV-2 Protein Synthesis for BVX-0320 and CoviDTH

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys"), announced that CDMO's global partner WuXi Biologics has completed the syn...

September 15, 2021 | News

Jemincare declared Ph I trial of its anti-SARS-CoV-2 neutralizing antibody

The clinical trial of JMB2002 was stated in January 2021. A single-center, randomized, double-blind, placebo-controlled, single-dose escalation phas...

September 14, 2021 | News

NeuExcell to reach the full potential of their innovative gene technology platform on accelerated timelines

FUJIFILM Diosynth Biotechnologies (FDB) will provide essential drug substance and drug product manufacturing, under accelerated timelines, for NeuExcell'...

September 13, 2021 | News

Odyssey Group Approved to Start Human Trial to Treat Concussion

The Company’s Clinical Trial Protocol was approved by the Alfred Ethics Committee and allows for the immediate start of the human trial. “We a...

September 08, 2021 | News

WuXi Biologics Received First Manufacturing License from Japan

WuXi Biologics (WuXi Bio) , a global company with leading open-access biologics technology platforms, today announced that it has received the Manufacturin...

September 02, 2021 | News

Stay Connected